TY - JOUR
T1 - RANKL coordinates multiple osteoclastogenic pathways by regulating expression of ubiquitin ligase RNF146
AU - Matsumoto, Yoshinori
AU - Larose, Jose
AU - Kent, Oliver A.
AU - Lim, Melissa
AU - Changoor, Adele
AU - Zhang, Lucia
AU - Storozhuk, Yaryna
AU - Mao, Xiaohong
AU - Grynpas, Marc D.
AU - Cong, Feng
AU - Rottapel, Robert
N1 - Funding Information:
Acknowledgments This work was supported by grants from the Canadian Institute for Health Research (CIHR) (grant 143420). RR is supported by the Princess Margaret Cancer Center and the Ontario Institute for Cancer Research (OICR): ITV. YM is supported by the Postdoctoral Fellowship for Research Abroad contributed by the Japan Society for the Promotion of Science, the Japan Rheumatism Foundation, the Sumitomo Life Social Welfare Services Foundation, and the Nakayama Science Foundation.
PY - 2017/4/3
Y1 - 2017/4/3
N2 - Bone undergoes continuous remodeling due to balanced bone formation and resorption mediated by osteoblasts and osteoclasts, respectively. Osteoclasts arise from the macrophage lineage, and their differentiation is dependent on RANKL, a member of the TNF family of cytokines. Here, we have provided evidence that RANKL controls the expression of 3BP2, an adapter protein that is required for activation of SRC tyrosine kinase and simultaneously coordinates the attenuation of ?-catenin, both of which are required to execute the osteoclast developmental program. We found that RANKL represses the transcription of the E3 ubiquitin ligase RNF146 through an NF-?B-related inhibitory element in the RNF146 promoter. RANKL-mediated suppression of RNF146 results in the stabilization of its substrates, 3BP2 and AXIN1, which consequently triggers the activation of SRC and attenuates the expression of ?-catenin, respectively. Depletion of RNF146 caused hypersensitivity to LPS-induced TNF-? production in vivo. RNF146 thus acts as an inhibitory switch to control osteoclastogenesis and cytokine production and may be a control point underlying the pathogenesis of chronic inflammatory diseases.
AB - Bone undergoes continuous remodeling due to balanced bone formation and resorption mediated by osteoblasts and osteoclasts, respectively. Osteoclasts arise from the macrophage lineage, and their differentiation is dependent on RANKL, a member of the TNF family of cytokines. Here, we have provided evidence that RANKL controls the expression of 3BP2, an adapter protein that is required for activation of SRC tyrosine kinase and simultaneously coordinates the attenuation of ?-catenin, both of which are required to execute the osteoclast developmental program. We found that RANKL represses the transcription of the E3 ubiquitin ligase RNF146 through an NF-?B-related inhibitory element in the RNF146 promoter. RANKL-mediated suppression of RNF146 results in the stabilization of its substrates, 3BP2 and AXIN1, which consequently triggers the activation of SRC and attenuates the expression of ?-catenin, respectively. Depletion of RNF146 caused hypersensitivity to LPS-induced TNF-? production in vivo. RNF146 thus acts as an inhibitory switch to control osteoclastogenesis and cytokine production and may be a control point underlying the pathogenesis of chronic inflammatory diseases.
UR - http://www.scopus.com/inward/record.url?scp=85018708083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018708083&partnerID=8YFLogxK
U2 - 10.1172/JCI90527
DO - 10.1172/JCI90527
M3 - Article
C2 - 28287403
AN - SCOPUS:85018708083
SN - 0021-9738
VL - 127
SP - 1303
EP - 1315
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 4
ER -